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Nowadays cell-based therapy is rarely in clinical practice because of the availability of 
appropriate cells. To apply cells therapeutically, they may not cause any immune 
response wherefore up to now mainly autologous cells were used. The amount of vital 
cells in patients is limited and under certain circumstances in highly degenerated 
tissues no vital cells are left. Moreover, the extraction of these cells is connected with 
additional surgery; also the expansion in vitro is difficult. Other approaches avoid these 
problems by using allo- or even xenogenic cells. These cells are more stable 
concerning their therapeutic behavior and can be produced in stock. To prevent an 
immune response caused by these cells, cell encapsulation (e.g. with alginate) can be 
performed. Certain studies showed that encapsulated allo- and xenogenic cells achieve 
promising results in treatment of several diseases. At this, stem cells, especially 
mesenchymal stem cells, are an interesting cell source for cell therapy approaches. 
This review deals on the one hand with cell therapy of encapsulated cells with focus on 
the use of stem cells and on the other hand with bioreactor systems for the expansion 
and differentiation of mesenchymal stem cells in reproducible and sufficient amounts 
for potential clinical use. 
ZUSAMMENFASSUNG 
Heutzutage werden zellbasierte Therapieansätze selten angewendet, da vor allem die 
Gewinnung geeigneter Zellen problematisch ist. Um Zellen therapeutisch einzusetzen, 
dürfen diese Zellen im Patienten keine Immunreaktion auslösen, weshalb bislang 
hauptsächlich körpereigene (autologe) Zellen verwendet werden. Vitale, autologe 
Zellen sind jedoch nur in begrenzter Menge im Patienten vorhanden und bei stark 
geschädigtem Gewebe unter Umständen gar nicht mehr. Zudem erfordert ihre 
Gewinnung zusätzliche Eingriffe für den Patienten. Auch ist eine Vermehrung ex vivo 
sehr (zeit)aufwendig. Andere Ansätze versuchen diese Problematik zu umgehen, 
indem allo- oder xenogene Zellen eingesetzt werden. Diese Zellen sind meist in ihren 
therapeutischen Eigenschaften stabiler und können auf Vorrat produziert werden. 
Damit diese Zellen keine Immunreaktion im Patienten auslösen, werden sie meist mit 
Alginat verkapselt. Diverse Studien zeigen, dass mit verkapselten allo- und xenogenen 
Zellen vielversprechende Ergebnisse bei der Behandlung diverser Krankheitsbilder 
erzielt wurden. Dabei stellen Stammzellen, insbesondere mesenchymale Stammzellen, 
eine besonders interessante Zellquelle für den therapeutischen Ansatz dar. Dieser 
Review behandelt sowohl eine mögliche klinische Anwendung verkapselter Zellen mit 
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dem Schwerpunkt auf dem Einsatz von Stammzellen als auch Systeme zur 
Expandierung und Differenzierung von mesenchymalen Stammzellen in 






Cell therapy is described as a process of introducing new cells in human body in order 
to treat a disease or to restore the function of a tissue. Thereby, cell therapy 
approaches often focus on degenerative diseases with or without gene therapy. No 
single cell or universal donor can be used for the treatment of all diseases, so that 
consequently the source and the desired function of the cell will dictate which cell type 
is most useful for each disease [1]. There are several forms of cell therapy: the 
transplantation of (i) autologous or allogenic stem cells, (ii) of mature, functional cells, 
(iii) of modified human cells that produce a needed substance, (iv) of transdifferentiated 
cells or (v) xenotransplantation.  
Although autologous cells have the advantage to cause no immune response and 
therefore are recommended for cell therapy, the retrieval of appropriate cells in 
sufficient amounts is difficult. Several diseases are congenital so that potential genetic 
dispositions causing the treated disease are still present in autologous cells. 
Furthermore, additional surgery is needed. For these reasons, allogenic or even 
xenogenic cells are attractive cell sources for regenerative medicine. To protect these 
cells from the immune response and to serve the cell survival, encapsulation of such 
cells is a feasible way.  
 
ENCAPSULATION OF CELLS FOR CLINICAL APPLICATION 
Cell encapsulation (Fig. 1) means the immobilization of cells within a semi-permeable 
membrane that allows the diffusion of small molecules (therapeutic proteins, nutrients, 
oxygen etc.) but protects the cell from the host’s immune system and also from 
mechanical stress [2, 3].  
There are many biomaterials like alginate, agarose and other polymers used for 
encapsulation. Existing materials are designed and modified to achieve ideal 
biocompatibility, degradation and physical properties depending on the field of 
application [4]. The most common material for cell encapsulation is alginate which 
forms a three-dimensional structure after reacting with multivalent cations. Similar to 
the available biomaterials, the formation methods are multifaceted as well. The most 
often described method is the formation of a core capsule covered by an outer layer. 
Due to the fact that this review does not focus on encapsulation technology, the 
biomaterials and the capsule formation were described shortly. For further reading 
several reviews concerning these topics are available [5-8]. 
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Many diseases, particularly chronic diseases, are based on a dysfunction of certain cell 
types. Cellular processes are very complex with many regulation and signaling 
pathways which cannot be imitated in vitro that easily. Therefore, it is very difficult to 
develop drugs or therapies for the treatment of such diseases based on in vitro studies 
because the results of these studies are often not able to project a drug effect in vivo. 
More successful is the implementation of cells which produce a therapeutic protein or 
restore the tissue function because this corresponds more to the natural behavior and 
can minimize unintentional side-effects. Compared to alternative therapies, the 
advantages of cell encapsulation are the use of allogenic (non-human) cells as 
alternative to the limited supply of donor tissue, the avoidance of permanent 
immunosupression and if desired the delivery of a therapeutic product over long time 
periods. In addition, genetically modified cells can be induced to produce any protein in 
vivo without changes in the patient’s genome. In comparison to the encapsulation of a 
therapeutic protein alone, the immobilization of cells allows a continuous and controlled 
release of a de novo synthesized protein with a constant rate giving rise to more 
physiological conditions. Moreover, in case of capsule damage, the fast release of high 
protein concentrations causing toxicity can be avoided. Due to these reasons, cell 
therapy with encapsulated cells seems to be a promising approach for many clinical 
applications. 
 
Primary cells used for cell therapy approaches 
Encapsulated primary cells are also known as bioorgans or biohybrids. Most common 
is the implementation of encapsulated islets of Langerhans mimicking the pancreas for 
the treatment of diabetes. For this disorder promising results from animal studies were 
obtained in allo- and xenotransplantation approaches [9-12]. Moreover, initial pilot 
clinical trials have been made that came to the conclusion that to some extent the 
function of the pancreas could be restored although the medication with insulin could 
not be completely set [13-15].  
Primary cells are also used in neurodegenerative disease such as Huntington’s 
disease. This disease is caused by the mutation of the protein hungtingtin which results 
in the damage of specific areas of the brain. Choroid plexus (CP) are areas in the brain 
which produce the cerebrospinal fluid (CSF) and act as a filtration system, removing 
metabolic waste, foreign substances, and excess neurotransmitters from the CSF. In 
this way the CP helps to maintain an extracellular environment required for optimal 
brain function [16]. In several studies concerning Huntington’s disease, CP was 
encapsulated and transplanted in the brain of laboratory animals [17, 18]. In a primate 
model of Huntington’s disease, encapsulated CP delivers neurotrophic growth factors 
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which prevent neurons from degeneration [18]. Furthermore, the secretion of 
neuroactive substances by encapsulated bovine chromaffin cells gave promising 
results in the treatment of chronic neuropathic pain, another neural disorder, in rat 
model [19]. 
 
Genetically engineered mature cells used for cell therapy approaches 
The number of primary cells is limited wherefore other cell sources are needed. One 
alternative is the genetic engineering of other mature cells to deliver the desired 
therapeutic protein. Which cell type will be used depends on the application as well as 
on processing, storage, availability and costs. For some applications, such as cerebral 
and cardiovascular disorders which are difficult to treat with common medication, 
encapsulated genetically improved cells could be more suited for therapy as common 
medicaments. 
Genetically engineered fibroblasts (recombinant GDNF [glial cell line-derived 
neurotrophic factor] production) were encapsulated and investigated concerning their 
ability to Parkinson disease. In a rat model, GDNF delivery improved the restoration of 
the nerve function [20, 21]. An encapsulated cell-based system consisting of 
engineered murine myoblasts was developed to deliver arylsulfatase A to the CNS of 
Metachromiatic Leukodystrophy patients [22]. To treat myocarditis, microencapsulated 
xenogenic CHO (chinese hamster ovary) cells expressing VEGF (vascular endothelial 
growth factor) were implanted into rats. The immune response was low for the 
encapsulated CHO cells. The VEGF expressing CHO cells significantly increased 
angiogenesis which was consisted with heart functional improvement [23]. Other 
approaches using encapsulated, genetically modified cells are the expression of β-
glucuronidase in epithelial cells treating mucopolysaccharidosis type VII [24], the 
expression of erythropoietin in myoblast [25, 26] or the expression of interleukin-6 in 
CHO cells inhibiting tumor progression [27]. Some cell therapy systems are still in 
clinical phase trials. For example, the safety of the transplantation of CNTF-expressing 
epithelial cells retarding retina degeneration is in phase I trial [28]. 
Although the availability of allo- or xenogenic mature cells is not a major problem, cell 
therapy based on encapsulated mature (allo-/xenogenic) cells still has some limitations. 
Up to now, the secretion of therapeutic proteins often is only short-time and immune 
response occurs in spite of cell encapsulation.  
 
Stem cells used for cell therapy approaches 
Stem cells could reduce the problem of the graft-versus-host disease, because for 
instance mesenchymal stem cells are often described as immune privileged [29, 30]. 
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Currently, stem cells still are only rarely used in the encapsulation technology and most 
research is based on in vitro studies. Nevertheless, the use of encapsulated stem cells 
could become one of the main objectives of this technique via implantation of 
(engineered) stem cells and direction of their specific differentiation.  
Stem cells can differentiate into every tissue cell within the organism. Cells 
characterized as stem cells have the ability of unlimited self-renewal to produce 
progeny exactly the same as the parental cell. Cancer cells have the property of self-
renewal as well, but they divide in an uncontrolled manner, whereas stem cell division 
is highly regulated. Therefore, a second requirement for stem cells is their ability to 
differentiate into a specialized cell type that becomes part of the healthy organism [31]. 
Originally, stem cells were distinguished into embryonic and adult stem cells depending 
on the developmental stage they originate. New research results have recovered that 
fully differentiated adult cells can dedifferentiate to embryonic stem cells and adult stem 
cells are also found in fetus, placenta and umbilical cord blood [32] suggesting that this 
classification is insufficient. Therefore, nowadays cells are sorted based on their 
biological properties in pluripotent and multipotent cells. Pluripotent cells can 
differentiate into all cell types of the body, multipotent cells only in cell types of a 
discrete germ line (endoderm, mesoderm and ectoderm) or a particular tissue. 
Pluripotent stem cells used in research and development are mainly isolated from the 
inner cell mass of blastocysts. However, technical hurdles and ethical concerns about 
the involvement of embryos impede the usage of such cells. An alternative to obtain 
pluripotent stem cells is the molecular manipulation of adult cells reprogramming them 
back into “induced pluripotent stem cells” [33]. Pluripotent stem cells have not yet been 
used therapeutically in humans because in animal studies formation of large tumors 
called teratomas was observed [34]. Moreover, no in vivo experiment with 
encapsulated pluripotent stem cells have been reported. Nevertheless, in animal 
studies, often with immunodeficient animals, these cells showed a high therapeutic 
potential and were used for the treatment of diabetes, spinal cord injury or visual 
impairment by creation of new insulin-producing cells, neurons or respectively retinal 
cells [35-37]. Pluripotent stem cells have also been investigated in animal models 
concerning several diseases such as Parkinson disease, muscular dystrophy, and 
heart failure [38-40]. 
Multipotent stem cells are found in almost every tissue in the human body. Cells with 
the highest differentiation potential are found in the gastrula and are evolutionary 
restricted to all cells of their germ layer. Unipotent cells have the lowest differentiation 
potential; they can become only one special cell type. These cells are typically found 
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within their organ and guarantee tissue integrity by serving as cell source to replace 
aged or injured cells if necessary [31].  
The first use of multipotent stem cells for cell therapy was the transplantation of bone 
marrow to cure several types of blood cancer [41]. This therapy is connected with a 
strong suppression of the immune system and with the availability of a genetically 
compatible donor. This means that to some extent multipotent stem cells are still in 
clinical practice. Nevertheless, the combination of stem cell and encapsulation 
technology has the potential to expand the current application range of stem cell 
approaches.  
Among several multipotent cell types, mesenchymal stem cells (MSCs) seem to be the 
ideal candidates for cell-based regeneration, because they are of high plasticity and 
have the capacity of multilineage differentiation [42]. In addition, they are accessible in 
sufficient quantities from bone marrow [43] and fat tissue [44] and, compared to other 
cell types, easy to expand and to manipulate [45]. Due to these facts, several 
experiments with encapsulated MSCs e.g. investigating their ability to form new bone 
and cartilage have been performed [46]. Furthermore, there are efforts for a potential 
use of encapsulated MSCs for intervertebral disc regeneration [47], heart ailments [48, 
49] and kidney regeneration [50].  
Often genetically engineered MSCs are used for therapy approaches as well. MSCs 
expressing the glucagon-like peptide-1 were investigated in clinical trials concerning 
traumatic brain injury (e.g. stroke). In this case, encapsulated MSCs were implanted 
cerebral and significantly improves cellular pathology in the brain [51]. Encapsulated 
MSCs, transfected with the gene of bone morphogenetic protein-2, a potent cytokine 
for bone formation, were found to induce bone formation [52]. Chondrogenesis could 
be enhanced in targeted cell population in vitro and in vivo after Sox-9 delivery from 
encapsulated and genetically improved MSCs [53]. In summary, results with 
encapsulated MSCs demonstrate their high potential for cell therapy and clinical use. 
Nevertheless, for an application of cell-based therapies, sufficient amounts of cells 
have to be expanded under reproducible and highly controlled conditions.  
 
CONTROLLED EXPANSION, CULTIVATION AND DIFFERENTIATION OF MSCS 
It has to be mentioned that unlike to traditional cell culture processes in which a 
secreted protein or a virus should be produced, the purpose of stem cell cultivation is to 
expand stem cells and sustain their multipotency, meaning that the cell itself is the 
desired product. Therefore, other culture requirements are necessary which include an 
efficient cell harvesting strategy. Moreover, the quality of the cells, in that case the 
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retention of self-renewal and differentiation ability, is critical and has to be examined for 
instance by detection of surface markers, morphology or other characteristics.  
In general, the selection of a bioreactor system for cell cultivation beyond bench scale 
is largely dependent on whether cells grow adherent or in suspension. As many other 
stem cell types, MSC are strictly anchorage dependent and therefore need a surface to 
attach and proliferate. Simple ways for the cultivation of adherent cells in larger 
quantities are monolayer culture flasks such as roller bottles or multiple plate vessels. 
Further, cells can be grown on carrier in stirred vessels (e.g. spinner flasks, fermentors) 
or bed reactors which are easy to operate and can be equipped with on-line monitoring 
instruments for environmental control. Beside the difficulties with scale-up and process 
control, monolayer cultures show several disadvantages especially for the cultivation of 
MSCs. It has been shown that in static monolayer cultures MSCs proliferate slower and 
the differentiation potential is affected as well [54]. Therefore, the use of bioreactors is 
an alternative to the static expansion in flasks. Bioreactors provide conditions similar to 
the in vivo situation of the cells including advantages such as efficient nutrient supply, 
waste removal, minimal shear stress and the possibility to control the cultivation via on-
line measurements of critical values [55]. Concerning bioreactor cultivation, an MSC 
expansion on 3D scaffolds in a perfusion system [56] and an expansion in a rotary cell 
culture system [57] have been published. Both studies showed an increase in MSC 
growth and higher cell densities compared to static cultures without an affection of the 
stem cell fate and the differentiation ability.  
In our work group, alternative concepts for human MSC (hMSC) expansion were 
investigated with regard to a high product quality and a reproducible and controlled 
cultivation. One approach comprised the expansion of hMSCs on non-porous 
microcarriers in spinner flasks. Although non-porous carriers have a reduced growth 
surface compared to porous carriers, the separation of the cells after the enzymatic 
detachment is simpler and leads to higher yields. Several carrier types were examined 
concerning cell growth and cell harvest including the investigation of different seeding 
densities and different enzymes for cell detachment. Our results showed that a 
decreased seeding density and the use of borosilicat carrier (e.g. Biosilon, RapidCell) 
were superior concerning cell growth and harvest. Further, the differentiation potential 
of the hMSCs was influenced neither by cultivation nor by harvest procedure [58]. 
Another approach was the expansion of the hMSCs on non-porous glass spheres in a 
fixed-bed reactor. Compared to suspension reactors this system has the advantage of 
a high volume-specific cell density and productivity, low shear stress, an easy medium 
exchange and a high process control [55]. In figure 2, a scheme of the reactor 
consisting of a glass cylinder and the corresponding periphery is shown. The oxygen 
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consumption of the cells was monitored on-line by measuring the oxygen concentration 
at the in- and outlet of the reactor whereas the metabolites were measured offline. Our 
results demonstrated that using this reactor system hMSCs can be expanded and 
harvested with a high cell density and vitality. The harvested stem cells were neither 
differentiated nor affected in their differentiation potential. The reactor system was 
designed very simple allowing its use as disposable system. Moreover, it is 
automatable and offers an on-line process control of several parameters. In summary, 
this system is suitable for an operation under GMP conditions [59, 60].  
While expansion and differentiation of hMSCs are often done in the same reactor and 
during the same cultivation, our workgroup decided to separate the cell expansion and 
the cell differentiation cultivation. After expansion, the hMSCs were harvested and 
encapsulated with alginate. The cell encapsulation was done by one of our cooperation 
partners (CellMed AG, Germany). The generated capsules called CellBeads®, are 
implantable therapeutic cell systems with potential for disease treatment in vivo. The 
CellBeads® itself form the bed of a fixed-bed system which is used to differentiate the 
hMSCs inside the capsule. Moreover, the bioreactor consists of a disposable syringe 
which can be used as implantation tool for the CellBeads® after finishing the 
differentiation. An overview of the differentiation system is shown in figure 3. Our 
results demonstrated that it is possible to differentiate hMSCs without significant loss of 
cell vitality with this reactor system. Moreover, the whole system can satisfy GMP-
requirements [61]. The presented studies indicate that it is possible to expand and 
differentiate hMSCs in good quality in bioreactor systems. Nonetheless, some 
problems are still to solve particularly with regard to the requirements of the process 
analytical technology (PAT) initiative of the Food and Drug Administration (FDA). In this 
case, the term PAT is defined as follows: ‘‘the agency considers PAT to be a system 
for designing, analyzing, and controlling manufacturing through timely measurements 
(i.e., during processing) of critical quality and performance attributes of raw and in-
process materials and processes, with the goal of ensuring final product quality. It is 
important to note that the term analytical in PAT is viewed broadly to include chemical, 
physical, microbiological, mathematical, and risk analysis conducted in an integrated 
manner.”[62] 
 
CONCLUSION AND OUTLOOK 
In summary, encapsulation technology especially in combination with stem cells 
achieves many interesting results with good aspects for a putative clinical application. 
To realize clinical practice some challenges in the field of material science and 
encapsulation technology and as well in the field of cell biology are to overcome.  
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On the material side, effort has been made in the availability of clinical-grade polymers. 
Alginate is often the material of the choice, but few years ago it was been a lack of a 
standardized polymer with low protein and endotoxin content. Now some companies 
(e.g. CellMed AG) have specialized on the purification of alginate guaranteeing clinical 
grade qualities. Another challenge is the formation of uniform capsules with excellent 
repeatability and reproducibility. In general, it seems to be a problem that cells 
agglutinate during encapsulation so that empty beads are produced. One prospect is to 
distinguish between empty and filled capsules. Moreover, many approaches need a 
defined stability of the cell capsules which has to be controlled by the material 
properties. Up to now, it is not possible to create materials with such degradation 
behaviors.  
On the biological side there is a need of suitable cells for immobilization. As outlined in 
the text, allogenic or even xenogenic cells are alternatives to patient’s own cells. 
Because of ethical reasons and a lower risk of virus transfer, allogenic cells were 
preferred. Mature, differentiated cells cannot be expanded that easy so that stem cells 
particularly MSCs are an interesting cell source. Characteristics of isolated hMSCs are 
varying very strong depending on the source and the method of isolation. This may be 
problematic in clinical approaches because up to now no marker for hMSC exists. 
Moreover, some isolated MSCs have lost their adipogenic or chondrogenic 
differentiation potential. As many primary cells, the characteristics of MSCs changed 
with increasing population doublings as well. To achieve a constant and reproducible 
cell quality a “standardized” hMSC is needed. A possibility is the use of hMSC-TERT 
cells which are genetically improved MSCs. In the genome of these cells the gene of 
the catalytic subunit of human telomerase is integrated that prevents telomere 
shortening. These cells can sustain much more population doublings than primary 
MSCs without any significant changes [63]. 
Beside the quality of the cells itself, the transplantation site of the cell capsules plays a 
critical role for the effort of the therapy. Among other things, these include the nutrition 
of the encapsulated cells and the need of vascularisation. To answers these questions 
there is still a lack of sufficient in vivo investigations. Moreover, the researchers have to 
clarify the point if cell encapsulation really protects the cells from host’s immune 
response. Most in vivo experiments have been done in immune suppressed animal or 
patients. Furthermore, some cell types such as MSCs are thought to be immune 
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A Schematic of encapsulated cells. Metabolites and waste products as well as 
therapeutic proteins can pass the capsules whereas components of the immune 
system cannot. 
 
B Photography of cells encapsulated with alginate (CellBeads®). The cells were 





Fixed-bed reactor system for stem cell expansion. The bioreactor consists of a glass 
cylinder filled with glass spheres as bed. Oxygen measurements are performed on-line 
with optical sensors (IPO2) at the in- and the outlet of the reactor. The cells are 
transferred into the reactor from an inoculum vessel. The following cultivation runs 
automatically with a perfusion of the reactor with preconditioned medium. Medium 
exchange is done if necessary whereby the exchanged medium is collected in the 
waste vessel. For the cell harvest, the reactor is automatically washed with PBS, 
followed by incubation with enzyme solution for cell detachment. The detachment is 





Fixed-bed reactor system for the differentiation of encapsulated stem cells. The 
bioreactor consists of a sterile plastic syringe filled with cell capsules as bed. The cell 
capsules are transferred into the reactor from an inoculum vessel. The following 
cultivation runs automatically with a perfusion of the reactor with preconditioned 
medium. Oxygen measurements are performed on-line with optical sensors (IPO2) at 
the in- and the outlet of the reactor. Medium exchange is done if necessary whereby 
the exchanged medium is collected in the waste vessel. After completion of the 
differentiation, the cell capsules are cryopreserved. Therefore, they are automatically 
washed with PBS, followed by addition of a cryoprotective medium. 
